SCHEMBL5583148

SCHEMBL5583148

CCOC(=O)c1ccc2[nH]c3c(c2c1)CCCCCC3=O

nearest known ligand 0.98

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.98
MAPT P10636 5/20 0.98
HSD17B10 Q99714 4/20 0.98
SMN1; SMN2 Q16637 2/20 0.98
ALOX15 P16050 2/20 0.98
L3MBTL1 Q9Y468 1/20 0.98
MEN1 O00255 3/20 0.71
KMT2A Q03164 3/20 0.71
RAB9A P51151 2/20 0.71
NPC1 O15118 1/20 0.71
MAPK1 P28482 4/20 0.69
PLK4 O00444 1/20 0.69
DAPK3 O43293 1/20 0.69
DYRK3 O43781 1/20 0.69
JAK2 O60674 1/20 0.69
PRKD3 O94806 1/20 0.69
MAP4K4 O95819 1/20 0.69
PIM1 P11309 1/20 0.69
RPS6KB1 P23443 1/20 0.69
CDK2 P24941 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5239415 0.99 KDM4E (1.00) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL4780133 0.83 MEN1 (1.00) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL6070647 0.83 KDM4E (0.72) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL1658107 0.82 KDM4E (0.71) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL4255908 0.82 KDM4E (0.71) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL2993573 0.81 MAPK1 (1.00) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL14366545 0.81 KDM4E (0.69) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL5583200 0.81 KDM4E (0.69) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL5583198 0.81 KDM4E (0.69) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL5583247 0.81 MAPT (0.69) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer IGF1R, KDR, ERBB2 KDM4E 1419/4885MAPT 4824/4885HSD17B10 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.